Kumagai Shogo, Ito Akihiro, Hashimoto Toru, Marumo Satoshi, Tokumasu Hironobu, Kotani Aya, Yamaki Haruka, Shirata Masahiro, Furuuchi Koji, Fukui Motonari, Ishida Tadashi
Department of Respiratory Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama, 710-0052, Japan.
Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
BMC Infect Dis. 2017 Jun 19;17(1):436. doi: 10.1186/s12879-017-2544-0.
Patients with Mycobacterium avium complex (MAC) lung disease (LD) have a heterogeneous prognosis. This study aimed to develop and validate a prognostic scoring model for these patients using independent risk factors for survival.
We retrospectively analyzed the data of patients with MAC-LD from two hospitals (cohort 1, n = 368; cohort 2, n = 118). Cohort 1 was evaluated using a multivariate Cox proportional hazards model to identify independent risk factors for overall survival (OS). A prognostic scoring model composed of these factors was developed, and cohort 1 was stratified into three groups according to risk using the log-rank test. Finally, the prognostic scoring model was validated using the data of cohort 2.
Seven independent risk factors for OS were selected from cohort 1, including the male sex, age ≥ 70 years, the presence of a malignancy, body mass index <18.5 kg/m, lymphocyte count <1000 cells/μL, serum albumin levels <3.5 g/dL, and fibrocavitary disease. The areas under the receiver operating characteristic curves for the prognostic scoring model were 0.84 [95% confidence interval (CI), 0.80 - 0.89] for cohort 1 and 0.84 (95% CI, 0.75 - 0.92) for cohort 2. The 5-year OS rates of patients stratified into low-risk, intermediate-risk, and high-risk groups were 97.6, 76.6, and 30.8%, respectively (P < 0.001), in cohort 1, and 97.2, 82.3, and 45.4%, respectively (P < 0.001), in cohort 2.
This study is the first to develop and validate a prognostic scoring model for patients with MAC-LD. This model may prove useful in clinical settings and practical in estimating the prognosis.
鸟分枝杆菌复合群(MAC)肺病(LD)患者的预后存在异质性。本研究旨在利用生存的独立危险因素,为这些患者开发并验证一种预后评分模型。
我们回顾性分析了两家医院MAC-LD患者的数据(队列1,n = 368;队列2,n = 118)。使用多变量Cox比例风险模型对队列1进行评估,以确定总生存(OS)的独立危险因素。由这些因素组成的预后评分模型被开发出来,并且使用对数秩检验根据风险将队列1分为三组。最后,使用队列2的数据对预后评分模型进行验证。
从队列1中选出了7个OS的独立危险因素,包括男性、年龄≥70岁、存在恶性肿瘤、体重指数<18.5 kg/m²、淋巴细胞计数<1000个细胞/μL、血清白蛋白水平<3.5 g/dL以及纤维空洞性疾病。预后评分模型在队列1中的受试者工作特征曲线下面积为0.84 [95%置信区间(CI),0.80 - 0.89],在队列2中为0.84(95%CI,0.75 - 0.92)。在队列1中,分为低风险、中风险和高风险组的患者5年OS率分别为97.6%、76.6%和30.8%(P < 0.001),在队列2中分别为97.2%、82.3%和45.4%(P < 0.001)。
本研究首次为MAC-LD患者开发并验证了一种预后评分模型。该模型在临床环境中可能有用,且在估计预后方面具有实用性。